Main Platforms / Products
• ADC/ARC Platforms: Site-specific conjugation with high homogeneity, high Drug-to-Antibody Ratio (DAR), enzyme-free process, produce soluble and stable ADC/ARC drug candidates. • Drug Bundles: Proprietary payload/linker designs. Multiple copies of payload molecules are conjugated to a “Multi-Arm Linker”, and connected to antibody through a controlled site-specific conjugation process. Payload/linker units are prepared in modules and assembled to customized bundles. Various cytotoxic drug bundles, e.g., Lenalidomide, MMAE, MMAF, SN38, DXd, DM1, PDB drug bundles and radionuclide bundles, e.g., DOTA bundles, are available. Assembled easily. Dual-payload designs are applicable. • TE-1146: Anti-CD38 ADC with lenalidomide bundles for multiple myeloma treatment. TE-1146 shows superior anti-tumor efficacy, good safety and stability, planning for IND filing between 2024-2025. • TE-1132: Anti-CA19-9 ARC with DOTA bundles for pancreatic cancer treatment & diagnosis. TE-1132 shows strong anti-tumor efficacy, 100% overall survival rate in tumor bearing mice models, planning for IND filing in 2025.
Business Interests
• Series A fundraising • Out-licensing ADC/ARC technology platforms to biotech, pharma, and CDMO • Out-licensing TE-1146 ADC (anti-CD38 for multiple myeloma treatment) and TE-1132 ARC (anti-CA19-9 for pancreatic cancer diagnosis / treatment) • Collaborations in research and development of ADC/ARC platforms
Contact Info
Kun-Po Li
Associate Director of External Collaboration and Clinical Development
+886-2-2651-2268
bd@temeds.com